Analysts compiled by Zacks predict that Pfizer will report fourth-quarter 2025 revenues of $16.93 billion and non-GAAP earnings per share of $0.57 when it issues results on February 3 before the market open. This consensus reflects a sequential revenue decline of approximately 8 percent from the third quarter, driven largely by seasonal fluctuations in vaccine and hospital product sales. Earnings forecasts have held within a narrow 4-cent band over the past month, suggesting limited near-term volatility in guidance revisions.

Company guidance for full-year 2025 anticipates total revenues between $61 billion and $64 billion, down from the pandemic peak of roughly $100 billion in 2022. Management attributes the majority of the adjustment to lower COVID-19 vaccine volumes, offset in part by ongoing demand for the influenza vaccine franchise and recently approved respiratory syncytial virus vaccine for older adults. Analysts expect core biopharma sales to grow mid-single digits year-over-year, underpinned by steady uptake of the pneumococcal conjugate vaccine.

Investors have expressed concern over the impending loss of exclusivity for key blockbusters such as Xeljanz and Ibrance between 2026 and 2028. However, Pfizer’s late-stage oncology portfolio, including the recently approved PD-1 inhibitor and next-generation antibody–drug conjugates, is projected to generate cumulative peak annual sales exceeding $8 billion. Additionally, the company’s MET-097i/MET-233i GLP-1/amylin combination has shown phase 2 weight-loss efficacy of over 15 percent at 36 weeks, positioning it as a potential best-in-class entrant.

With a forward dividend yield of approximately 6.7 percent, Pfizer remains among the highest-yielding large-cap pharmaceutical issuers. The company has maintained or increased its payout for 14 consecutive years, distributing over $9 billion in dividends during 2025. At its current payout ratio near 60 percent of adjusted earnings, management has signaled confidence in free cash flow generation to support both income returns and targeted share repurchases over the next three years.